This company listing is no longer active
Halo Collective Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Halo Collective's earnings have been declining at an average annual rate of -37.9%, while the Pharmaceuticals industry saw earnings growing at 26.5% annually. Revenues have been growing at an average rate of 11.7% per year.
Wichtige Informationen
-37.9%
Wachstumsrate der Gewinne
66.1%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 23.1% |
| Wachstumsrate der Einnahmen | 11.7% |
| Eigenkapitalrendite | -367.4% |
| Netto-Marge | -393.9% |
| Letzte Ertragsaktualisierung | 30 Jun 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Halo Collective Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 23 | 18 | -72 | 25 | 0 |
| 31 Mar 23 | 22 | -76 | 32 | 0 |
| 31 Dec 22 | 25 | -84 | 36 | 0 |
| 30 Sep 22 | 28 | -95 | 38 | 0 |
| 30 Jun 22 | 32 | -99 | 43 | 0 |
| 31 Mar 22 | 34 | -99 | 44 | 0 |
| 31 Dec 21 | 36 | -95 | 42 | 0 |
| 30 Sep 21 | 33 | -54 | 39 | 0 |
| 30 Jun 21 | 31 | -47 | 31 | 0 |
| 31 Mar 21 | 27 | -42 | 25 | 0 |
| 31 Dec 20 | 22 | -41 | 22 | 0 |
| 30 Sep 20 | 19 | -33 | 24 | 0 |
| 30 Jun 20 | 20 | -35 | 27 | 0 |
| 31 Mar 20 | 24 | -33 | 26 | 0 |
| 31 Dec 19 | 28 | -28 | 24 | 0 |
| 30 Sep 19 | 28 | -17 | 17 | 0 |
| 30 Jun 19 | 25 | -17 | 14 | 0 |
| 31 Mar 19 | 17 | -15 | 11 | 0 |
| 31 Dec 18 | 11 | -14 | 9 | 0 |
| 30 Sep 18 | 10 | -15 | 11 | 0 |
| 30 Jun 18 | 10 | -11 | 10 | 0 |
| 31 Mar 18 | 10 | -10 | 10 | 0 |
| 31 Dec 17 | 10 | -9 | 9 | 0 |
| 31 Dec 16 | 5 | 0 | 1 | 0 |
Qualität der Erträge: HALO is currently unprofitable.
Wachsende Gewinnspanne: HALO is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: HALO is unprofitable, and losses have increased over the past 5 years at a rate of 37.9% per year.
Beschleunigtes Wachstum: Unable to compare HALO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: HALO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (77.9%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: HALO has a negative Return on Equity (-367.44%), as it is currently unprofitable.